37,033 Shares in Biohaven Ltd. (NYSE:BHVN) Bought by Raymond James Financial Inc.

Raymond James Financial Inc. purchased a new position in Biohaven Ltd. (NYSE:BHVN - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 37,033 shares of the company's stock, valued at approximately $1,384,000.

Several other hedge funds also recently bought and sold shares of the company. Teacher Retirement System of Texas raised its holdings in Biohaven by 31.6% during the fourth quarter. Teacher Retirement System of Texas now owns 23,320 shares of the company's stock valued at $871,000 after acquiring an additional 5,600 shares during the period. Bank of New York Mellon Corp raised its stake in Biohaven by 9.1% during the 4th quarter. Bank of New York Mellon Corp now owns 295,078 shares of the company's stock valued at $11,021,000 after purchasing an additional 24,703 shares during the period. JPMorgan Chase & Co. lifted its holdings in Biohaven by 85.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 809,448 shares of the company's stock worth $40,448,000 after purchasing an additional 372,737 shares in the last quarter. American Century Companies Inc. boosted its stake in Biohaven by 9.5% in the 4th quarter. American Century Companies Inc. now owns 558,761 shares of the company's stock worth $20,870,000 after purchasing an additional 48,286 shares during the period. Finally, Alliancebernstein L.P. grew its holdings in Biohaven by 6.6% during the 4th quarter. Alliancebernstein L.P. now owns 96,236 shares of the company's stock valued at $3,594,000 after buying an additional 5,951 shares in the last quarter. Institutional investors own 88.78% of the company's stock.

Biohaven Stock Performance

NYSE BHVN traded down $0.07 during trading hours on Wednesday, reaching $19.11. The stock had a trading volume of 1,810,648 shares, compared to its average volume of 1,171,004. Biohaven Ltd. has a 52-week low of $15.79 and a 52-week high of $55.70. The stock has a market cap of $1.95 billion, a P/E ratio of -2.04 and a beta of 1.18. The stock has a fifty day moving average of $24.26 and a 200 day moving average of $36.04.

Biohaven (NYSE:BHVN - Get Free Report) last released its quarterly earnings data on Monday, March 3rd. The company reported ($1.85) EPS for the quarter, missing the consensus estimate of ($1.56) by ($0.29). On average, equities research analysts forecast that Biohaven Ltd. will post -8.9 EPS for the current year.

Insider Transactions at Biohaven

In other news, Director John W. Childs acquired 32,700 shares of the company's stock in a transaction dated Tuesday, March 4th. The shares were acquired at an average price of $30.47 per share, with a total value of $996,369.00. Following the purchase, the director now directly owns 2,320,571 shares of the company's stock, valued at $70,707,798.37. This trade represents a 1.43 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Company insiders own 16.00% of the company's stock.

Analysts Set New Price Targets

Several equities analysts recently weighed in on BHVN shares. William Blair raised shares of Biohaven to a "strong-buy" rating in a research note on Thursday, April 24th. Robert W. Baird cut their price target on Biohaven from $60.00 to $57.00 and set an "outperform" rating for the company in a report on Monday, April 28th. HC Wainwright reiterated a "buy" rating and set a $54.00 price objective on shares of Biohaven in a research report on Tuesday, March 4th. Morgan Stanley reduced their target price on shares of Biohaven from $69.00 to $63.00 and set an "overweight" rating on the stock in a report on Friday, March 7th. Finally, Royal Bank of Canada restated an "outperform" rating and set a $61.00 price objective on shares of Biohaven in a research report on Tuesday, March 4th. Fourteen analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Biohaven currently has a consensus rating of "Buy" and an average target price of $62.54.

About Biohaven

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.